Findings

What do systematic reviews say?

7 questions · 7 findings · 7 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 2 · 28.6%Moderate 1 · 14.3%High 0 · 0%

Intervention not reported

All‐cause mortality (ticlopidine vs placebo) · patients with type 2 diabetes mellitus

The intervention showed no clear difference in all‐cause mortality (ticlopidine vs placebo) (moderate certainty).

1 finding from 1 review

Adenosine‐diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes… 2012 · Cochrane Headline outcomes only
RR 1.29 [0.71, 2.32]
1 study · 335 participants
Moderate

Intervention not reported

All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus

The intervention showed no clear difference in all‐cause mortality a. Intervention vs placebo [30 weeks to 4.75… (low certainty).

1 finding from 1 review

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus 2013 · Cochrane Headline outcomes only
RR 1.46 [0.87, 2.45]
2 studies · 553 participants
Low

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

All‐cause mortality

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 50 participants
Very low

Fluoxetine vs placebo

All‐cause mortality · overweight or obese adults

The review found no eligible studies for this question.

1 finding from 1 review

Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acarbose vs placebo

All‐cause mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether acarbose changes all‐cause mortality compared with placebo (very low certainty).

1 finding from 1 review

Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in… 2018 · Cochrane Headline outcomes only
RR 0.98 [0.82, 1.18]
3 studies · 8069 participants
Very low

Vitamin D vs placebo or no intervention

All‐cause mortality · healthy participants or recruited among the general population; individuals diagnosed with a specific disease in a stable phase or with…

Vitamin D may leads to lower all‐cause mortality compared with placebo or no intervention (low certainty).

1 finding from 1 review

Vitamin D supplementation for prevention of cancer in adults 2014 · Cochrane Headline outcomes only
RR 0.93 [0.88, 0.98]
15 studies · 49866 participants
Low

Summary of findings: pioglitazone monotherapy vs placebo

All‐cause mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
2.38 [0.54, 10.5]
4 studies · 1156 participants
Very low